GlobalData’s senior medical analyst says the ban will add to a downward trend for Illumina in the Chinese market.

Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a shifting ...

The MiSeq desktop sequencer offers low throughput flowcells and long read lengths. It is best for small whole-genome sequencing, targeted gene sequencing, metagenomics, and CRISPR validation. The ...

The advent of next-generation sequencing has made possible genome analysis at previously unattainable depth. Roche, Illumina and Life Technologies, among others, have developed well-established ...

The funding will be used to support the commercial rollout of Element’s benchtop instrument for next-generation sequencing (NGS), Aviti, which is a competitor to Illumina technology, like its ...

Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN ...

(RTTNews) - Illumina, Inc. (ILMN) responded on Monday to the notice from the China Ministry of Commerce stating that it is not permitted to export sequencing ... for a new generation of investors ...

Gene-sequencing giant Illumina is laying off 96 employees from its San Diego headquarters, according to paperwork filed with the state. This workforce reduction comes at a time when Illumina is ...

Medical Device Network · JHVEPhoto via Shutterstock. China has banned the import of Illumina’s next-generation sequencing (NGS) sequencers as part of retaliatory measures against fresh tariffs ...